CA2727941A1 - Antibodies against extracellular domains 2 and 3 or her2 - Google Patents

Antibodies against extracellular domains 2 and 3 or her2 Download PDF

Info

Publication number
CA2727941A1
CA2727941A1 CA2727941A CA2727941A CA2727941A1 CA 2727941 A1 CA2727941 A1 CA 2727941A1 CA 2727941 A CA2727941 A CA 2727941A CA 2727941 A CA2727941 A CA 2727941A CA 2727941 A1 CA2727941 A1 CA 2727941A1
Authority
CA
Canada
Prior art keywords
cancer
affinity ligand
her2
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2727941A
Other languages
English (en)
French (fr)
Inventor
Mathias Uhlen
Johan Rockberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atlas Therapeutics AB
Original Assignee
Atlas Therapeutics AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atlas Therapeutics AB filed Critical Atlas Therapeutics AB
Publication of CA2727941A1 publication Critical patent/CA2727941A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2727941A 2008-06-13 2008-12-12 Antibodies against extracellular domains 2 and 3 or her2 Abandoned CA2727941A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2008155676A JP2010006705A (ja) 2008-06-13 2008-06-13 Ｈｅｒ２サブセット
JP2008-155676 2008-06-13
US7635208P 2008-06-27 2008-06-27
US61/076352 2008-06-27
PCT/SE2008/000694 WO2009151356A1 (en) 2008-06-13 2008-12-12 Antibodies against extracellular domains 2 and 3 or her2

Publications (1)

Publication Number Publication Date
CA2727941A1 true CA2727941A1 (en) 2009-12-17

Family

ID=40427661

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2727941A Abandoned CA2727941A1 (en) 2008-06-13 2008-12-12 Antibodies against extracellular domains 2 and 3 or her2

Country Status (8)

Country Link
US (1) US20110158988A1 (enExample)
EP (1) EP2294088A1 (enExample)
JP (1) JP2010006705A (enExample)
KR (2) KR20130026418A (enExample)
CN (1) CN102099376A (enExample)
AU (1) AU2008357729A1 (enExample)
CA (1) CA2727941A1 (enExample)
WO (1) WO2009151356A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101759209B1 (ko) 2010-01-22 2017-07-19 성균관대학교산학협력단 Ｈｅｒ－２ 과발현 유방암 세포 또는 조직에 특이적으로 결합할 수 있는 핵산 압타머 및 그 용도
US8609095B2 (en) 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
AU2016201799B2 (en) * 2010-05-27 2017-09-07 Genmab A/S Monoclonal antibodies aganst HER2 epitope
CA3051311A1 (en) * 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
EP2575880B1 (en) * 2010-05-27 2019-01-16 Genmab A/S Monoclonal antibodies against her2 epitope
JP2014514314A (ja) 2011-04-20 2014-06-19 ゲンマブ エー／エス Ｈｅｒ２およびｃｄ３に対する二重特異性抗体
CN105017425B (zh) * 2014-04-30 2018-02-16 京天成生物技术(北京)有限公司 抗her2中和活性单克隆抗体及其应用
JP6971319B2 (ja) 2016-12-28 2021-11-24 グリーン・クロス・ラブ・セル・コーポレイション キメラ抗原受容体及びそれを発現するナチュラルキラー細胞
EP3712178A4 (en) 2017-11-14 2021-08-11 Green Cross Lab Cell Corporation ANTI-HER2 ANTIBODIES OR ANTIGIBODY FRAGMENT THEREOF AND CHIMERAIR ANTIGEN RECEPTOR WITH IT
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
AU2018383096A1 (en) * 2017-12-11 2020-06-11 Medizinische Universitaet Wien A method of producing a vaccine composition and uses thereof
WO2020036869A1 (en) 2018-08-16 2020-02-20 Emd Millipore Corporation Closed bioprocessing device
US20210238305A1 (en) * 2019-03-01 2021-08-05 Remegen Co., Ltd. Antibody for her2 concomitant diagnosis immunohistochemical detection and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US5783404A (en) * 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
EP1239866A4 (en) * 1999-12-10 2005-02-09 Epimmune Inc INDUCTION OF HER2 / NEU CELLULAR IMMUNE RESPONSES USING PEPTIDE AND NUCLEIC ACID-CONTAINING COMPOSITIONS
IL159177A0 (en) * 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
CN1136917C (zh) * 2001-10-10 2004-02-04 北京迪威华宇生物技术有限公司 一种卡介苗热休克蛋白65和多表位her-2抗原融合蛋白重组蛋白疫苗
AU2003296330A1 (en) * 2002-12-10 2004-06-30 Epimmune Inc. Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
AU2005287404B2 (en) * 2004-07-22 2009-05-07 Genentech, Inc. HER2 antibody composition
ES2348312T3 (es) * 2006-04-13 2010-12-02 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. Vacuna her-2/neu a base de múltiples péptidos.
CA2655205A1 (en) * 2006-06-12 2007-12-21 Receptor Biologix Inc. Pan-cell surface receptor- specific therapeutics
CN101165068B (zh) * 2006-10-18 2011-09-21 上海复旦张江生物医药股份有限公司 抗HER2/ErbB2抗原的单克隆抗体及其制备方法和药物组合物

Also Published As

Publication number Publication date
WO2009151356A1 (en) 2009-12-17
CN102099376A (zh) 2011-06-15
AU2008357729A8 (en) 2011-02-03
US20110158988A1 (en) 2011-06-30
AU2008357729A1 (en) 2009-12-17
KR20110036534A (ko) 2011-04-07
JP2010006705A (ja) 2010-01-14
KR20130026418A (ko) 2013-03-13
EP2294088A1 (en) 2011-03-16

Similar Documents

Publication Publication Date Title
US20110158988A1 (en) Antibodies against extracellular domains 2 and 3 or her2
US20240343824A1 (en) Binding molecules that inhibit cancer growth
ES2826774T3 (es) Anticuerpo que se une a ERBB-2 y ERBB-3
DK2494359T3 (en) PODXL protein in colorectal cancer
CN104662044B (zh) 用于治疗ror1癌症并抑制转移的抗体和疫苗
JP7209464B2 (ja) ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体
TW201713684A (zh) 用於對抗食道癌及其他癌症的新穎胜肽及胜肽的組合物
EP2396346B1 (en) Rbm3 protein in colorectal cancer prognostics
Kim et al. Generation of a human antibody that inhibits TSPAN8-mediated invasion of metastatic colorectal cancer cells
US20250122303A1 (en) Treatment and prevention of cancer using her3 antigen-binding molecules
CN112812179B (zh) 高亲和力高特异性抗cmtm6单克隆抗体及其用途
CN112823168A (zh) 结合her2的四聚体多肽
CN111656194A (zh) Tnbc划分和治疗的方法和组合物
HK40062651A (en) Binding molecules that inhibit cancer growth
HK40051469A (en) Her2-binding tetrameric polypeptides
Panke Fakultät für Chemie Lehrstuhl für Biotechnologie
CN112010975A (zh) Lag3结合片段及其用途
HK1253914B (en) Binding molecules that inhibit cancer growth

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20141212